INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30001, 26703, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30002, 29770, 'Valproic acid', 'Depressive Disorder', 'Antiepileptic drugs can increase depression and suicidal thoughts or behaviors in patients receiving these drugs for any indication.  Patients should be monitored for the emergence or worsening of depression, suicidal thoughts and unusual changes in mood or behavior.  Caregivers and family should be alert for the emergence or worsening of symptoms.  Behaviors of concern should be reported immediately to the healthcare providers.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30003, 3029, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30004, 3031, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30005, 12047, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30006, 12121, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30007, 17129, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30008, 17258, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30009, 17262, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30010, 17264, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30011, 22532, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30012, 26703, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30013, 29770, 'Valproic acid', 'Liver Diseases', 'The use of valproate derivatives is contraindicated in patients with hepatic disease or significant hepatic dysfunction.  Serious and potentially fatal hepatotoxicity has been reported in patients treated with these agents.  The risk appears to be greatest in children less than 2 years of age--particularly those on multiple anticonvulsants and those with congenital metabolic disorders, severe seizure disorders accompanied by intellectual disability, or organic brain disease--and decreases considerably in progressively older patient groups.  Therapy with valproate products should be administered with extreme caution and as a sole agent in patients with risk factors for valproate-related hepatotoxicity.  In reported cases, the onset has generally been within the first 6 months of treatment and may be preceded by nonspecific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, nausea, vomiting, and a loss of seizure control.  Patients should be monitored closely for appearance of these symptoms, and therapy withdrawn immediately if significant hepatic dysfunction occurs.  Liver function tests should be performed prior to initiating therapy and at frequent intervals thereafter, especially during the first 6 months.  However, clinicians should bear in mind that transient, dose-related, asymptomatic elevations in serum transaminase, amylase and ammonia levels may commonly occur and often return to normal with or without dosage adjustment.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30014, 3029, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30015, 3031, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30016, 12047, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30017, 12121, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30018, 17129, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30019, 17258, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30020, 17262, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30021, 17264, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30022, 22532, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30023, 26703, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30024, 29770, 'Valproic acid', 'Urea Cycle Disorders, Inborn', 'Valproic acid and derivative products are contraindicated in patients with known urea cycle disorders (UCD), as hyperammonemic encephalopathy, sometimes fatal, has been reported on these patients following the initiation of treatment.  Prior to the initiation of therapy, the evaluation for UCD should be considered in patients with history of unexplained encephalopathy or comma, encephalopathy associated with a protein load, pregnancy- related or postpartum encephalopathy, unexplained intellectual disability, or history of elevated plasma ammonia or glutamine.  Also, those with family history of UCD or family history of unexplained infant deaths.  Patients who develop symptoms of hyperammonemic encephalopathy while receiving valproate therapy should receive prompt treatment including treatment discontinuation and be evaluated for underlying urea cycle disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30025, 3029, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30026, 3031, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30027, 12047, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30028, 12121, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30029, 17129, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30030, 17258, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30031, 17262, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30032, 17264, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30033, 22532, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30034, 26703, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30035, 29770, 'Valproic acid', 'HIV Infections', 'Some in vitro studies suggest that valproate stimulates the replication of the HIV and CMV viruses under certain experimental conditions.  The clinical consequences are unknown, and the relevance of these findings is uncertain for patients receiving maximally suppressive antiretroviral therapy.  However, this should be borne in mind when interpreting the results from regular monitoring of the viral load in HIV infected patients receiving valproate or when following CMV infected patients clinically.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30036, 3029, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30037, 3031, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30038, 12047, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30039, 12121, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30040, 17129, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30041, 17258, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30042, 17262, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30043, 17264, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30044, 22532, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30045, 26703, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30046, 29770, 'Valproic acid', 'Thrombocytopenia', 'The use of valproate derivatives may be associated with dose-related thrombocytopenia, the incidence of which is generally low but has been reported at up to 27% in one study using high dosages (approximately 50 mg/kg/day of valproic acid).  In that study, platelet counts returned to normal in all patients, some despite continued treatment.  Valproate may also inhibit the secondary phase of platelet aggregation, although this effect is unlikely to be of clinical significance except during the concomitant use of other drugs that affect coagulation.  However, altered bleeding time, ecchymosis, petechiae, bruising, hematoma formation, epistaxis, and frank hemorrhage have been reported rarely.  Hypofibrinogenemia has also been observed.  Therapy with valproate products, particularly at high dosages, should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  The manufacturers recommend platelet counts and coagulation tests prior to initiating therapy and at periodic intervals thereafter, as well as before planned surgery.  The dosage should be reduced or the drug withdrawn if clinical evidence of hemorrhage, bruising, or a disorder of hemostasis or coagulation occurs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30047, 3029, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30048, 3031, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30049, 12047, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30050, 12121, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30051, 17129, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30052, 17258, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30053, 17262, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30054, 17264, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30055, 22532, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30056, 26703, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30057, 29770, 'Valproic acid', 'Thyroid Diseases', 'The manufacturers state that there have been reports of altered thyroid function tests associated with the use of valproate.  However, no specific information is given.  Clinicians should be cognizant of this potential effect when prescribing or administering valproate products to patients with thyroid disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30058, 3029, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30059, 3031, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30060, 12047, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30061, 12121, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30062, 17129, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30063, 17258, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30064, 17262, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30065, 17264, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30066, 22532, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30067, 26703, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30068, 29770, 'Valproic acid', 'Diabetes Mellitus', 'Valproate is partially eliminated in the urine as a ketone-containing metabolite, which may lead to a false interpretation of the urine ketone test.  Clinicians should be cognizant of this interaction when prescribing or administering valproate products to patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30069, 0, 'Vemurafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30070, 0, 'Vemurafenib', 'Skin Neoplasms', 'Cutaneous squamous cell carcinoma, keratoacanthoma, and melanoma occurred at a higher incidence in patients receiving vemurafenib.  Potential risk factors associated included age (> 65 years), prior skin cancer, and chronic sun exposure.  It is recommended to perform dermatologic evaluations prior to initiation of therapy and periodically thereafter as clinically indicated.  Consider dermatologic monitoring for 6 months following discontinuation of vemurafenib.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30071, 0, 'Vemurafenib', 'Stevens-Johnson Syndrome', 'Severe dermatologic reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and mild to severe photosensitivity can occur in patients treated with vemurafenib.  Consider dose modifications for intolerable >= Grade 2 photosensitivity.  It is recommended to advise patients to avoid sun exposure, wear protective clothing and use a broad-spectrum UVA/UVB sunscreen and a suitable lip balm when outdoors while on vemurafenib treatment.  Permanently discontinue vemurafenib in patients who experience a severe dermatologic reaction.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30072, 0, 'Vemurafenib', 'Hepatic Insufficiency', 'Liver injury leading to functional hepatic impairment, including coagulopathy or other organ dysfunction may occur with the use of vemurafenib.  Based on a population pharmacokinetic analysis to evaluate the effect of hepatic impairment, no dose adjustment is recommended for patients with mild and moderate hepatic impairment.  The appropriate dose of vemurafenib has not been established in patients with severe hepatic impairment.  It is recommended to monitor transaminases, alkaline phosphatase, and bilirubin before initiation of treatment and monthly during treatment, or as clinically indicated; and to manage laboratory abnormalities with dose reduction, treatment interruption, or treatment discontinuation as appropriate.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30073, 0, 'Vemurafenib', 'Long QT Syndrome', 'Vemurafenib can cause dose dependent QT prolongation which may lead to an increased risk for ventricular arrhythmias, including Torsade de Pointes.  It is recommended not to start treatment in patients with uncorrectable electrolyte abnormalities, QTc > 500 ms, or long QT syndrome, or in patients who are taking medicinal products known to prolong the QT interval.  Evaluate patients prior to and following treatment initiation or after dose modification for QTc prolongation, evaluate ECG and electrolytes (including potassium, magnesium, and calcium) periodically, and thereafter as clinically indicated.  Vemurafenib should be withhold in patients who develop QTc > 500 ms.  Upon recovery to QTc <= 500 ms, restart at a reduced dose and it should be permanently discontinued if the QTc interval remains > 500 ms and increased > 60 ms from pre-treatment values after controlling cardiac risk factors for QT prolongation (e.g., electrolyte abnormalities, congestive heart failure, and bradyarrhythmias).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30074, 0, 'Vemurafenib', 'Kidney Diseases', 'Renal failure, including acute interstitial nephritis and acute tubular necrosis may occur with the use of vemurafenib.  Based on a population pharmacokinetic analysis, no dose adjustment is recommended for patients with mild and moderate renal impairment.  The appropriate dose of vemurafenib has not been established in patients with severe renal impairment.  It is recommended to measure serum creatinine before initiation of therapy and periodically during treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30075, 0, 'Vemurafenib', 'Vision Disorders', 'Uveitis, blurry vision, and photophobia can occur in patients treated with vemurafenib.  Monitor patients for signs and symptoms of uveitis.  Care must be exercised when using this agent in patients with ophthalmological complications.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30076, 0, 'Verteporfin', 'Porphyrias', 'The use of verteporfin is contraindicated in patients with porphyria.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30077, 0, 'Verteporfin', 'Hepatic Insufficiency', 'Verteporfin therapy should be considered carefully in patients with moderate to severe hepatic impairment or biliary obstruction since there is no clinical experience with verteporfin in such patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30078, 0, 'Berotralstat', 'Kidney Diseases', 'Berotralstat has not been studied in patients with end-stage renal disease (CrCl < 15 mL/min or patients requiring hemodialysis), and its use is not recommended in these patients.  No dosage adjustment is recommended for patients with mild, moderate or severe renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30079, 2066, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30080, 6622, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30081, 6625, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30082, 6627, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30083, 12220, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30084, 12222, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30085, 15848, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30086, 19879, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30087, 19880, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30088, 21019, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30089, 21106, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30090, 21107, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30091, 21108, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30092, 21109, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30093, 29139, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30094, 29141, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30095, 29182, 'Verapamil', 'Aortic Valve Stenosis', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with advanced aortic stenosis.  CCBs whose pharmacologic effect is partially dependent on their ability to reduce afterload (e.g., diltiazem, nicardipine, nifedipine, verapamil) may be of less benefit in these patients due to a fixed impedance to flow across the aortic valve and may, in fact, worsen rather than improve myocardial oxygen balance.  Rarely, heart failure has developed following the initiation of these CCBs, particularly in patients receiving concomitant beta-blocker therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30096, 2066, 'Verapamil', 'Atrioventricular Block', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with severe bradyarrhythmia, sick sinus syndrome (unless a functioning pacemaker is present), or heart block greater than the first degree (unless a functioning pacemaker is present).  CCBs like bepridil, diltiazem and verapamil have a negative effect on AV conduction and the SA node and may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30097, 6622, 'Verapamil', 'Atrioventricular Block', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with severe bradyarrhythmia, sick sinus syndrome (unless a functioning pacemaker is present), or heart block greater than the first degree (unless a functioning pacemaker is present).  CCBs like bepridil, diltiazem and verapamil have a negative effect on AV conduction and the SA node and may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30098, 6625, 'Verapamil', 'Atrioventricular Block', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with severe bradyarrhythmia, sick sinus syndrome (unless a functioning pacemaker is present), or heart block greater than the first degree (unless a functioning pacemaker is present).  CCBs like bepridil, diltiazem and verapamil have a negative effect on AV conduction and the SA node and may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30099, 6627, 'Verapamil', 'Atrioventricular Block', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with severe bradyarrhythmia, sick sinus syndrome (unless a functioning pacemaker is present), or heart block greater than the first degree (unless a functioning pacemaker is present).  CCBs like bepridil, diltiazem and verapamil have a negative effect on AV conduction and the SA node and may exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (30100, 12220, 'Verapamil', 'Atrioventricular Block', 'The use of some calcium channel blockers (CCBs) is contraindicated in patients with severe bradyarrhythmia, sick sinus syndrome (unless a functioning pacemaker is present), or heart block greater than the first degree (unless a functioning pacemaker is present).  CCBs like bepridil, diltiazem and verapamil have a negative effect on AV conduction and the SA node and may exacerbate these conditions.', '3', '', 'DDInter', 0);
